Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07335497 · ClinicalTrials.gov registry record · Phase 1
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Locally Advanced/Metastatic Solid Tumors, sponsored by Crescent Biopharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
- 5
- Study locations
NCT07335497: Recruiting Phase 1 study of Locally Advanced/Metastatic Solid Tumors, sponsored by Crescent Biopharma.
NCT07335497 is a Phase 1 study of Locally Advanced/Metastatic Solid Tumors that is actively recruiting participants, run by Crescent Biopharma. The registered enrollment target is 290 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (383% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07335497, a Phase 1 study of Locally Advanced/Metastatic Solid Tumors, is actively recruiting participants, sponsored by Crescent Biopharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Primary Outcome
Per cohort
Conditions Studied
Interventions
- DRUG CR-001
Study Locations (5)
Florida
- Clinical Study Site - Orlando
- Clinical Study Site - Sarasota
Colorado
- Clinical Study Site - Denver
Tennessee
- Clinical Study Site - Nashville
Texas
- Clinical Study Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
What NCT07335497 shows while recruiting
NCT07335497 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (383% higher).
The record links to 1 condition, with Locally Advanced/Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which CR-001 is the first listed.
NCT07335497 lists 5 locations in 4 states (Florida, Colorado, Tennessee).
Frequently Asked Questions
What is clinical trial NCT07335497 about?
NCT07335497 is a clinical study titled "CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors". The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
What is the current status of trial NCT07335497?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2026-02-17. Estimated completion is 2029-02.
What conditions does trial NCT07335497 study?
This clinical trial studies the following conditions: Locally Advanced/Metastatic Solid Tumors.
What interventions are being tested in trial NCT07335497?
The interventions under investigation include: CR-001 (DRUG).
Who is sponsoring clinical trial NCT07335497?
This trial is sponsored by Crescent Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07335497 being conducted?
This trial has 5 study locations across Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced/Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07335497's enrollment target sits among peer trials
290 138th of 2000 higher than 1,862 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI